Otras inmunoterapias en desarrollo

– Targeting inflammation to improve regulatory T cell therapy for immunopathologies. Proc Natl Acad Sci U S A. 2022;119(44):e2215271119.
– Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med 2022; 387:1264-1278.
– Responsiveness to interleukin-15 therapy is shared between tissue-resident and circulating memory CD8+ T cell subsets. Proc Natl Acad Sci U S A. 2022;119(44):e2209021119.
– Inhibition of FOXP3 by stapled alpha-helical peptides dampens regulatory T cell function. Proc Natl Acad Sci U S A. 2022;119(44):e2209044119.
– HSCT for adults with immunodeficiencies. Blood, 2022;140(14):1580–1581.